ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Risk assessment combining STS risk estimate, frailty, major organ system dysfunction, and procedure-specific impediments

Risk assessment combining STS risk estimate, frailty, major organ system dysfunction, and procedure-specific impediments
  Low risk
(must meet ALL criteria in this column )
Intermediate risk
(any 1 criterion in this column)
High risk
(any 1 criterion in this column)
Prohibitive risk
(any 1 criterion in this column)
STS PROM* <4% AND 4 to 8% OR >8% OR Predicted risk with surgery of death or major morbidity (all-cause) >50% at 1 y OR
Frailty None AND 1 Index (mild) OR ≥2 Indices (moderate to severe) OR
Major organ system compromise not to be improved postoperativelyΔ None AND 1 Organ system OR No more than 2 organ systems OR ≥3 Organ systems OR
Procedure-specific impediment None Possible procedure-specific impediment Possible procedure-specific impediment Severe procedure-specific impediment
CKD: chronic kidney disease; CNS: central nervous system; CVA: stroke; DLCO2: diffusion capacity for carbon dioxide; FEV1: forced expiratory volume in 1 s; GI: gastrointestinal; INR: international normalized ratio; LV: left ventricular; PROM: predicted risk of mortality; RV: right ventricular; STS: Society of Thoracic Surgeons; VKA: vitamin K antagonist.
* Use of the Society of Thoracic Surgeons Predicted Risk of Mortality (STS PROM) to predict risk in a given institution with reasonable reliability is appropriate only if institutional outcomes are within one standard deviation of STS average observed/expected ratio for the procedure in question.
¶ Seven frailty indices: Katz Activities of Daily Living (independence in feeding, bathing, dressing, transferring, toileting, and urinary continence) and independence in ambulation (no walking aid or assist required or 5-meter walk in <6 s). Other scoring systems can be applied to calculate no, mild-, or moderate-to-severe frailty.
Δ Examples of major organ system compromise: Cardiac-severe LV systolic or diastolic dysfunction or RV dysfunction, fixed pulmonary hypertension; CKD stage 3 or worse; pulmonary dysfunction with FEV1 <50% or DLCO2 <50% of predicted; CNS dysfunction (dementia, Alzheimer's disease, Parkinson's disease, CVA with persistent physical limitation); GI dysfunction-Crohn's disease, ulcerative colitis, nutritional impairment, or serum albumin <3.0; cancer-active malignancy; and liver-any history of cirrhosis, variceal bleeding, or elevated INR in the absence of VKA therapy.
Examples: tracheostomy present, heavily calcified ascending aorta, chest malformation, arterial coronary graft adherent to posterior chest wall, or radiation damage.
Reproduced from: Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63:e57. Table used with the permission of Elsevier Inc. All rights reserved.
Graphic 95631 Version 4.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟